Gabriel Diem
Overview
Explore the profile of Gabriel Diem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaderer V, Diem G, Posch W, Jakschitz T, Bonn G, Bellmann-Weiler R, et al.
Respir Res
. 2024 Feb;
25(1):102.
PMID: 38419061
Seasonally circulating viruses, such as Influenza, as well as newly emerging viruses and variants thereof, and waning immunity urge the need for safe, easy-to-use and inexpensive drugs to protect from...
2.
Diem G, Dichtl S, Zaderer V, Lass-Florl C, Reindl M, Lupoli G, et al.
Microbiol Spectr
. 2023 Aug;
:e0179323.
PMID: 37551989
Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted...
3.
Pichler R, Diem G, Hackl H, Koutnik J, Mertens L, D Andrea D, et al.
Front Immunol
. 2023 Jul;
14:1202157.
PMID: 37520557
BCG is the most efficient adjuvant therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC). Both innate and adaptive immune responses have been implicated in BCG-mediated effects. BCG vaccination can boost innate...
4.
Diem G, Jager M, Dichtl S, Bauer A, Lass-Florl C, Reindl M, et al.
Microbiol Spectr
. 2023 Apr;
11(3):e0516322.
PMID: 37098903
Rising breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/5 led to the performance of various studies investigating systemic immunity and neutralizing antibodies in sera, but mucosal...
5.
Dichtl S, Diem G, Jager M, Zaderer V, Lupoli G, Dachert C, et al.
Antiviral Res
. 2023 Mar;
213:105581.
PMID: 36965526
The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal...
6.
Jager M, Diem G, Sahanic S, Fux V, Griesmacher A, Lass-Florl C, et al.
J Infect Dis
. 2023 Mar;
228(2):160-168.
PMID: 36869832
Background: The emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants BA.1, BA.2, and BA.4/5 demonstrate higher transmission and infection rates than previous variants of concern. To evaluate effectiveness...
7.
Diem G, Lafon E, Bauer A, Lass-Florl C, Reindl M, Wilflingseder D, et al.
J Clin Microbiol
. 2022 Aug;
60(9):e0106522.
PMID: 36036600
No abstract available.
8.
Jager M, Sonnleitner S, Dichtl S, Lafon E, Diem G, Walder G, et al.
Front Immunol
. 2022 Jul;
13:868361.
PMID: 35833113
Background: Residents of nursing homes are one of the most vulnerable groups during the severe acute syndrome coronavirus 2 (SARS-CoV-2) pandemic. The aim of this study was to characterize cellular...
9.
Posch W, Bermejo-Jambrina M, Steger M, Witting C, Diem G, Hortnagl P, et al.
mBio
. 2021 Oct;
12(5):e0240821.
PMID: 34634939
Complement-opsonized HIV-1 triggers efficient antiviral type I interferon (IFN) responses in dendritic cells (DCs), which play an important role in protective responses at the earliest stages in retroviral infection. In...
10.
Lafon E, Diem G, Witting C, Zaderer V, Bellmann-Weiler R, Reindl M, et al.
Front Immunol
. 2021 Jul;
12:684014.
PMID: 34194438
T cells play a fundamental role in the early control and clearance of many viral infections of the respiratory system. In SARS-CoV-2-infected individuals, lymphopenia with drastically reduced CD4 and CD8...